Search company, investor...

Pro-Cure Therapeutics

Founded Year



Other Investors | Alive

About Pro-Cure Therapeutics

Prostate Cancer - Pro-Cure Therapeutics - Enabling the development of a cure for prostate cancer based on stem cells

Headquarters Location

Biocentre Innovation Way, York Science Park

YO10 5NY,

United Kingdom

Missing: Pro-Cure Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pro-Cure Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Pro-Cure Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pro-Cure Therapeutics is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Pro-Cure Therapeutics Patents

Pro-Cure Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Stem cells, Oncology, Transcription factors, Biotechnology, Immunology


Application Date


Grant Date



Related Topics

Stem cells, Oncology, Transcription factors, Biotechnology, Immunology



Pro-Cure Therapeutics Frequently Asked Questions (FAQ)

  • When was Pro-Cure Therapeutics founded?

    Pro-Cure Therapeutics was founded in 2001.

  • What is Pro-Cure Therapeutics's latest funding round?

    Pro-Cure Therapeutics's latest funding round is Other Investors.

  • Who are the investors of Pro-Cure Therapeutics?

    Investors of Pro-Cure Therapeutics include Aberdeen Asset Management, White Rose Technology Seedcorn Fund and Pipejoin Technologies.

  • Who are Pro-Cure Therapeutics's competitors?

    Competitors of Pro-Cure Therapeutics include OncoMed Pharmaceuticals, Gamida Cell, GANYMED Pharmaceuticals, Novus Therapeutics, LIDDS and 12 more.

Compare Pro-Cure Therapeutics to Competitors


Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA


Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.


Signase is a cancer therapeutics company developing small molecule inhibitors of a critical cell replication pathway to inhibit tumor growth. Signase was spun out of the M. D. Anderson Cancer Center.

Falcon Genomics

Falcon Genomics, Inc. is focused on functional genomics as a tool for cancer diagnostics and therapeutics.

Progression Therapeutics

Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo.

Regenetech Logo

Regenetech develops and offers intellectual property licenses in the area of Adult Stem Cell Expansion and therapeutic applications of adult stem cells. Regenetech uses a technology discovered by NASA in space experiments for growing three-dimensional (3D) stem cells in a weightless environment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.